296 studies found for:    sirolimus cancer | Open Studies
Show Display Options
Download search resultsDownload the search results for:
sirolimus cancer | Open Studies (296 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Phase I/Ib Dose Escalation & Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression
Conditions: Head and Neck Cancer;   Lung Cancer
Interventions: Drug: Ceritinib (LDK378);   Drug: Ceritinib (LDK378) 750 mg;   Drug: Everolimus
2 Recruiting Anakinra or Denosumab and Everolimus in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Everolimus;   Drug: Anakinra;   Drug: Denosumab
3 Not yet recruiting Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Recombinant NY-ESO-1 Protein;   Drug: Sirolimus
4 Unknown  A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Rapamycin;   Drug: Trastuzumab
5 Recruiting Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Conditions: Breast Cancer;   Solid Tumors
Interventions: Drug: Everolimus;   Drug: Trastuzumab;   Drug: Letrozole
6 Recruiting Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Sirolimus
7 Recruiting Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Metformin
8 Recruiting A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Vandetanib;   Drug: Everolimus
9 Recruiting Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
Conditions: Recurrent Bladder Carcinoma;   Stage II Bladder Cancer;   Stage III Bladder Cancer;   Stage IV Bladder Cancer
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Sirolimus;   Procedure: Therapeutic Conventional Surgery
10 Recruiting Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
Conditions: Renal Cancer;   Chromophobe Renal Cell Carcinoma;   Birt-Hogg-Dube Syndrome
Intervention: Drug: Everolimus
11 Recruiting Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and Other Indications
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Valproic Acid;   Drug: Cetuximab
12 Recruiting A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Condition: HER-2 Positive Breast Cancer
Interventions: Drug: Everolimus;   Drug: Vinorelbine;   Drug: Trastuzumab
13 Recruiting Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
Condition: Recurrent Childhood Brain Tumor
Interventions: Device: Tumor biology testing;   Drug: Temozolomide;   Drug: Etoposide;   Drug: Sorafenib;   Drug: Everolimus;   Drug: Erlotinib;   Drug: Dasatinib
14 Recruiting Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: everolimus;   Drug: carboplatin;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis
15 Recruiting Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Hydroxychloroquine;   Drug: Sirolimus;   Drug: Vorinostat
16 Recruiting Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
Conditions: Central Nervous System Metastases;   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: lapatinib ditosylate;   Drug: everolimus;   Drug: capecitabine;   Other: laboratory biomarker analysis
17 Recruiting Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Device: Levonorgestrel Intrauterine Device (LIUD);   Drug: Everolimus;   Behavioral: Questionnaire
18 Recruiting Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Conditions: Solid Tumor;   Kidney Cancer
Interventions: Drug: pazopanib;   Drug: everolimus
19 Recruiting Women's Triple-Negative First-Line Study: Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
20 Recruiting S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Condition: Kidney Cancer
Interventions: Drug: everolimus;   Other: placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years